Market Research Trends

The Continuous Renal Replacement Therapy (CRRT) market had a value of US$1 billion in 2021, and is predicted to reach US$ 1.68 billion by 2027, growing at a CAGR of 7.7% between 2021 and 2027. CRRT involves the removal of solutes from the blood using hemofiltration, hemodialysis, or both, and differs from other renal replacement therapies like Intermittent Hemodialysis (IHD), as it can last up to 24 hours in an ICU. The major players in the market are incorporating technological advancements in acute therapy. In 2019, Baxter International Inc. introduced their TherMax blood warmer and PrisMax system for TPE and continuous renal replacement therapy. Software integration is also being explored as a unique method to execute CRRT safely and effectively. Baxter's PRISMAFLEX system and B. Braun's Diapact Continuous Renal Replacement Therapy (CRRT) allow for crucial blood filtration, and offer adaptable platforms for individualized treatments at the patients' convenience. Competi...

The global Continuous Renal Replacement Therapy Market was worth US$ 1 Billion in the year 2021 and is poised to reach US$ 1.68 Billion by the year 2027 at a CAGR of 7.7% between 2021 and 2027. Continuous Renal Replacement Treatment includes the removal of solutes from the blood using hemofiltration, hemodialysis, or both. The therapy lasts nearly 24 hours in an Intensive Care Unit (ICU), distinguishing it from other types of standard renal replacement therapies such as IHD (Intermittent Hemodialysis), which lasts 4-6 hours (at times, even less). The leading players are embracing technological improvements in acute therapy. For example, Baxter International Inc. cleared their integrated TherMax blood warmer and PrisMax system for TPE (therapeutic plasma exchange) and continuous renal replacement therapy in 2019. Software integration is being considered as a unique technique for executing continuous renal replacement therapy efficiently and safely. Baxter has developed the PRISMA...

The global Continuous Renal Replacement Therapy Market was worth US$ 1 Billion in the year 2021 and is poised to reach US$ 1.68 Billion by the year 2027 at a CAGR of 7.7% between 2021 and 2027. Continuous Renal Replacement Therapy is inclusive of removal of solute from the blood through hemofiltration or hemodialysis or both combined. The therapy lasts for close to 24 hours in an Intensive Care Unit (ICU), thereby rendering it different from the other types of traditional renal replacement therapies like IHD (Intermittent Hemodialysis), which comprises 4-6 hours (at times, even less). The key participants are into adopting technological advancements regarding acute therapy. For instance – Baxter International Inc., in the year 2019, did clear its integrated TherMax blood warmer and PrisMax system for TPE (therapeutic plasma exchange) and continuous renal replacement therapy. Software integration is being looked upon as a novel tool for performing continuous renal replacement the...